GMP Cell Manufacturing Sits at the Center of Stem Cell Transplant Care
Baylor College of Medicine is recruiting a Tissue Engineer I to support the Center for Cell and Gene Therapy’s GMP manufacturing operation in Houston, where sterile processing and product release sit directly between the laboratory and the patient’s infusion chair. The role is built around hematopoietic stem cell products and commercial T-cell products used in pediatric and adult transplant and cell and gene therapy programs. In practical terms, this is the work that keeps cellular therapies from becoming theoretical: cells must be processed, cryopreserved, stored, tested, documented, and cleared before they ever reach the bedside.
The position is anchored in current Good Manufacturing Practice standards, which means technical skill alone is not enough. Every step must be reproducible, traceable, and defensible to both institutional reviewers and federal regulators. When a patient is waiting for transplant or investigational therapy, there is no room for ambiguity in donor eligibility, chain-of-custody documentation, or release criteria.
The Release Decision Is a Clinical Gate, Not a Paper Exercise
The job centers on cryopreservation, thawing, and release testing for cellular products before infusion. That includes coordination of sterility and identity testing, such as BACTEC culture and flow cytometry, to verify that the material being released is both safe and what it is supposed to be. In cell therapy, contamination is not a clerical defect; it is a direct threat to a profoundly vulnerable host, especially in patients whose immune systems are already compromised by conditioning therapy, malignancy, or inherited disease.
One sentence captures the pressure of the role: a single out-of-specification result can alter whether a product is usable, delayed, or rejected.
Because the program supports both established transplant protocols and investigational products still in clinical development, the same laboratory floor must serve two different regulatory realities. Licensed products move through one set of requirements, while IND-stage therapies demand the kind of documentation and process control that can withstand FDA scrutiny during development and submission. The Tissue Engineer I helps bridge that gap by working with clinical and regulatory staff to ensure that each product meets release expectations before use.
Documentation Carries the Same Weight as the Cells Themselves
The role places unusual emphasis on records, and for good reason. Batch records, donor eligibility files, chain-of-custody forms, and release checklists are not administrative extras; they are the evidence trail that proves a cellular product was manufactured under control and handled correctly from collection to infusion. In a setting where autologous and allogeneic products can travel through multiple hands, even a small documentation error can create a downstream safety concern.
The post also involves maintaining processing and release records in Epic and in the Center for Cell and Gene Therapy’s laboratory information systems. That combination matters because clinical teams need rapid access to product status, while quality systems need durable records for audits, sponsor monitoring visits, and internal review. When a transplant physician asks whether a product is ready, the answer has to be supported by data, testing, and traceable documentation—not memory.
Equipment Reliability Is Part of Patient Safety
The work extends beyond bench processing into qualification, calibration verification, and routine maintenance of GMP equipment, including controlled-rate freezers, biosafety cabinets, and the CliniMACS plus system. These platforms are central to consistent cell handling, and their reliability shapes whether cells survive cryopreservation, retain viability after thaw, and remain fit for infusion. A freezer that drifts out of specification or a cabinet that fails environmental checks can compromise an entire batch, which is why equipment oversight sits inside the job description rather than beside it.
The manufacturing environment also requires structured participation in process validation and method development. The Tissue Engineer I helps draft and revise standard operating procedures, validation worksheets, and stability-study documents as new assays and processes are introduced. That is the invisible labor behind every evolving therapy platform: as cell and gene therapy expands, laboratories must keep pace without sacrificing control.
Adventitious Agent Screening Reflects the Risk Profile of Cellular Therapies
The posting includes sample preparation and testing for adventitious agent screening on master cell banks and investigational products, including sterility, HPV, and mycoplasma testing. Those assays speak to the microbiologic risk that follows any living product through manufacturing. Unlike small-molecule drugs, cellular products can carry biologic material that must be actively screened for contamination before clinical use.
This is where the role becomes more than technical support. By helping prepare and test products for microbial risk, the engineer contributes to the basic safety architecture of transplant and cell therapy programs. In a domain where patients may already have little physiologic reserve, avoiding even low-level contamination is essential.
Regulatory Work Now Runs Through the Laboratory Bench
The position also includes preparing documentation for FDA information requests, FDA and IRB audits, sponsor monitoring visits, and QA reviews. That scope reflects a larger shift in cellular therapy: manufacturing is no longer a back-room activity hidden from clinical care. It is a regulated extension of the treatment pathway, with release decisions and validation data often determining whether a therapy can advance from development to routine clinical use.
The ideal candidate will bring a Bachelor’s degree in a basic science or related field, with two years of relevant experience, while a master’s degree is preferred. Prior work in a cGMP or clinical laboratory setting, especially cell processing, cryopreservation, or cell and gene therapy manufacturing, would fit the demands of the role, as would familiarity with culture-based sterility testing and electronic health record systems. The schedule is full time, Monday through Friday, 8 a.m. to 5 p.m., though the posting makes clear that flexibility for evenings, overnights, and weekends may be required.
This is a permanent academic role with a salary range of $70,618 to $83,080, and it comes with a specific eligibility constraint: no visa sponsorship is available. For cell therapy programs, staffing decisions affect throughput, compliance, and turnaround time as much as they affect payroll. When transplant schedules move quickly, the manufacturing unit has to move with them, and the margin for error is measured in patient safety, not convenience.
Cell Therapy Programs Depend on Quiet, Exacting Work
The most important feature of this job is not headline-grabbing innovation. It is disciplined execution. Cryopreserved products must survive freezing and thawing; sterility and identity testing must be accurate; release documentation must satisfy clinical, institutional, and federal standards; and every deviation must be tracked before a product reaches a patient.
In that setting, the Tissue Engineer I becomes one of the people who determines whether a cell therapy can move from manufacture to infusion without delay. The posting does not describe a new experimental endpoint or a clinical trial result. It describes the infrastructure that makes those trials and treatments possible, and the operational pressure rises whenever a product sits at the border between development and delivery.